|
|
Article: Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies.
- Article from:
- PR Newswire
- Article date:
- April 14, 2008
|
Copyright informationCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA, data showing that commercial anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche), cetuximab (Erbitux(R); Bristol-Myers Squibb, Imclone, Merck Serono), and panitumumab (Vectibix(R); Amgen) can be converted to highly potent BiTE(R) antibodies (1). Likewise, the anti-IgE antibody omalizumab (Xolair(R); Genentech, Novartis) for the treatment of asthma can also be ...
Related newspaper, magazine, and journal articles:
|
|
Article: Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action.
PR Newswire;
November 6, 2007 ;
700+ words
......action of Micromet's bispecific BiTE antibody therapeutics. The studies were...Immunotherapy(2), respectively. BiTE antibodies are designed to transiently...platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting...
|
|